May 10, 2021 12:29 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Exempt oxygen tanks, Covid medicines from taxes: Mamata Banerjee writes to PM Modi | Delhi lockdown extended by another week, metro to remain shut this time | 21 dead in Rajasthan village after Covid-infected corpse buried without protocol | PM Modi's actions to stifle criticisms 'inexcusable', govt must own up Covid mistakes: Lancet | India records 4.03 lakh fresh Covid cases, 4,092 deaths in last 24 hours
ISSAR Pharma to out license its peptide-based New Chemical Entities Drug Technology
Representative image of Peptide

ISSAR Pharma to out license its peptide-based New Chemical Entities

India Blooms News Service | @indiablooms | 04 May 2021, 09:55 pm

Hyderabad/IBNS: ISSAR Pharmaceuticals, a leading iIndian pharma company specialising in peptide technology and peptide drug innovation, announced they will license out their peptide-based New Chemical Entities (NCEs), with pre-IND filing and US Patent.

According to the company, the potential collaboration will help it to design and deliver novel peptide-based drugs for various unmet healthcare needs of the population, and making it affordable and accessible for better health outcomes.

The company’s founder and chairman, Ramakrishna Reddy Isanaka said, “We take pride in being India’s first ever company to conduct phase-1 clinical trials, and launch the first ever indigenous peptide drug, Melgain in market for the treatment of Vitiligo in 2004.”

ISSAR Pharmaceuticals uses solid-phase peptide synthesis as the technology of choice, and has the capability to synthesize custom peptides, API peptides and cosmetic peptides at all scales within a short duration.

ISSAR has also developed their second New Chemical Entity called Xylentra, which, according to the company, is the first ever peptide drug in the world for the treatment of burn wounds and microbial infections.

ISSAR’s FDA - compliant state-of-the-art peptide manufacturing facility of 62,000 sq. ft., is located in Hyderabad’s famous business district, Genome Valley.